JP2020023567A5 - - Google Patents

Download PDF

Info

Publication number
JP2020023567A5
JP2020023567A5 JP2019194647A JP2019194647A JP2020023567A5 JP 2020023567 A5 JP2020023567 A5 JP 2020023567A5 JP 2019194647 A JP2019194647 A JP 2019194647A JP 2019194647 A JP2019194647 A JP 2019194647A JP 2020023567 A5 JP2020023567 A5 JP 2020023567A5
Authority
JP
Japan
Prior art keywords
xaa
absent
amino acid
seq
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019194647A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020023567A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2020023567A publication Critical patent/JP2020023567A/ja
Publication of JP2020023567A5 publication Critical patent/JP2020023567A5/ja
Pending legal-status Critical Current

Links

JP2019194647A 2013-06-28 2019-10-25 アミノ酸及びペプチド接合体及び接合方法 Pending JP2020023567A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ612654 2013-06-28
NZ61265413 2013-06-28

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016522936A Division JP6659535B2 (ja) 2013-06-28 2014-06-27 アミノ酸及びペプチド接合体及び接合方法

Publications (2)

Publication Number Publication Date
JP2020023567A JP2020023567A (ja) 2020-02-13
JP2020023567A5 true JP2020023567A5 (enExample) 2020-03-26

Family

ID=52142779

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016522936A Expired - Fee Related JP6659535B2 (ja) 2013-06-28 2014-06-27 アミノ酸及びペプチド接合体及び接合方法
JP2019194647A Pending JP2020023567A (ja) 2013-06-28 2019-10-25 アミノ酸及びペプチド接合体及び接合方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016522936A Expired - Fee Related JP6659535B2 (ja) 2013-06-28 2014-06-27 アミノ酸及びペプチド接合体及び接合方法

Country Status (8)

Country Link
US (2) US10576144B2 (enExample)
EP (2) EP3013789B1 (enExample)
JP (2) JP6659535B2 (enExample)
CN (2) CN105555756B (enExample)
AU (3) AU2014300503B2 (enExample)
CA (1) CA2953747A1 (enExample)
TW (2) TW201920229A (enExample)
WO (1) WO2014207708A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103189072B (zh) 2010-09-22 2018-02-09 因纳瓦克私人有限公司 免疫刺激方法
AU2014300503B2 (en) 2013-06-28 2018-11-22 Auckland Uniservices Limited Amino acid and peptide conjugates and conjugation process
RU2017126206A (ru) 2014-12-23 2019-01-25 Маргарет Анне БРИМБЛЕ Аминокислотные и пептидные конъюгаты и направления их использования
AU2017223267B2 (en) * 2016-02-26 2021-07-22 Auckland Uniservices Limited Amino acid and peptide conjugates and conjugation process
MX2020002084A (es) * 2017-08-30 2020-03-24 Auckland Uniservices Ltd Conjugados de peptido, proceso de conjugacion y usos de los mismos.
CN111479823A (zh) * 2017-11-06 2020-07-31 奥克兰联合服务有限公司 肽缀合物cgrp受体拮抗剂及其制备方法和用途
ES3053993T3 (en) 2017-12-21 2026-01-28 Axelia Oncology Pty Ltd Optimised compounds
EA202092269A1 (ru) 2018-03-23 2020-12-14 Кармот Терапьютикс, Инк. Модуляторы сопряженных с g-белком рецепторов
CN113795584B (zh) 2019-03-04 2025-09-30 大学健康网络 T细胞受体及其使用方法
AU2020231927A1 (en) * 2019-03-04 2021-09-30 University Health Network T cell receptors and methods of use thereof
KR20210149049A (ko) 2019-03-04 2021-12-08 유니버시티 헬스 네트워크 T 세포 수용체 및 이의 사용 방법
AU2020245270A1 (en) 2019-03-25 2021-10-14 University Health Network T cell receptors and methods of use thereof
KR20220050873A (ko) 2019-06-26 2022-04-25 악셀리아 온콜로지 피티와이 리미티드 신규한 분자
EP4141110A4 (en) 2020-04-24 2025-04-09 Sf Biotech Laboratuvar Danismanlik Anonim Sirketi Method for producing particles of bacteriophages of the genus levivirus
CN111921001A (zh) * 2020-08-19 2020-11-13 兰州百源基因技术有限公司 一种用于伤口愈合的薄膜及其制备方法
CN117980325A (zh) 2021-05-13 2024-05-03 卡莫特治疗学股份有限公司 G-蛋白偶联受体的调节剂
US20250276995A1 (en) * 2022-04-08 2025-09-04 Chugai Seiyaku Kabushiki Kaisha Production method for peptide compound

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0014815A3 (de) 1978-12-20 1980-10-29 Ciba-Geigy Ag Peptidderivate, Verfahren zu deren Herstellung und Zwischenprodukte sowie pharmazeutische Präparate mit einer dieser Verbindungen
US4939240A (en) 1983-03-04 1990-07-03 Health Research, Inc. Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy
US4918164A (en) 1987-09-10 1990-04-17 Oncogen Tumor immunotherapy using anti-idiotypic antibodies
DE3813821A1 (de) 1988-04-22 1989-11-02 Hoechst Ag Synthetische vakzine gegen die maul- und klauenseuche und verfahren zu deren herstellung
US6074650A (en) 1985-06-24 2000-06-13 Hoechst Aktiengesellschaft Membrane anchor/active compound conjugate, its preparation and its uses
US6024964A (en) 1985-06-24 2000-02-15 Hoechst Aktiengesellschaft Membrane anchor/active compound conjugate, its preparation and its uses
US4743543A (en) 1985-09-09 1988-05-10 Coulter Corporation Method for enhancing and/or accelerating immunoassay detection of human carcinoma tumor associated antigen in a pathology sample
US4921790A (en) 1987-04-24 1990-05-01 Research Corporation Tumor specific assay for CA125 ovarian cancer antigen
US5053489A (en) 1988-01-29 1991-10-01 Dana-Farber Cancer Institute, Inc. Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma-associated antigen
US4963484A (en) 1988-01-29 1990-10-16 Dana-Farber Cancer Institute, Inc. Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma-associated antigen
US4914021A (en) 1988-03-04 1990-04-03 New England Deaconess Hospital Corporation Carcinoma orosomucoid-related antigen, a monoclonal antibody thereto, and their uses
US4921789A (en) 1988-04-20 1990-05-01 New England Deaconess Hospital Corporation Marker for colorectal carcinoma and methods of detecting the same
JPH02172946A (ja) 1988-12-26 1990-07-04 Shinetsu Sakusan Vinyl Kk カルボン酸アルケニルエステルの製造方法
US5110911A (en) 1989-11-02 1992-05-05 Biomira, Inc. Human tumor-associated thomsen-friedenreich antigen
EP0627940B1 (en) 1992-03-05 2003-05-07 Board of Regents, The University of Texas System Use of immunoconjugates for the diagnosis and/or therapy of vascularized tumors
SG55079A1 (en) 1992-12-11 1998-12-21 Dow Chemical Co Multivalent single chain antibodies
ATE244888T1 (de) 1993-02-05 2003-07-15 Epigen Inc Humanes carcinoma-antigen (hca), hca antikörper, hca immunoassays, aufzeichnungsmethoden und therapy
US6310180B1 (en) 1993-06-21 2001-10-30 Vanderbilt University Method for synthesis of proteins
DE4331011A1 (de) 1993-09-13 1995-03-16 Bayer Ag Nukleinsäuren-bindende Oligomere mit C-Verzweigung für Therapie und Diagnostik
AUPM446594A0 (en) 1994-03-16 1994-04-14 Csl Limited Cytotoxic t-cell epitopes identified within epstein-barr virus
JPH08248579A (ja) 1995-03-14 1996-09-27 Mitsubishi Paper Mills Ltd ハロゲン化銀写真感光材料及びその処理方法
US5994294A (en) 1996-02-02 1999-11-30 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
AUPO007396A0 (en) 1996-05-24 1996-06-20 Csl Limited Ebv ctl epitopes
US6251603B1 (en) * 1996-10-03 2001-06-26 Ludwig Institute For Cancer Research Method for determining status of a cancerous condition by determining antibodies to NY-ESO-1 in a patient sample
US6982085B2 (en) 1997-04-02 2006-01-03 Statens Serum Institut TB diagnostic based on antigens from M. tuberculosis
US7037510B2 (en) 1997-04-18 2006-05-02 Statens Serum Institut Hybrids of M. tuberculosis antigens
AUPO784197A0 (en) 1997-07-10 1997-08-07 Csl Limited Treatment of nasopharyngeal carcinoma
US5965535A (en) * 1997-09-12 1999-10-12 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
DE69837273T2 (de) 1997-10-08 2008-01-31 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Menschliches krebsantigen ny eso-1/cag-3 und dazu kodierendes gen
IL125608A0 (en) 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
AU768574B2 (en) 1999-02-01 2003-12-18 Eisai R&D Management Co., Ltd. Immunological adjuvant compound
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
JP4776852B2 (ja) 2000-01-28 2011-09-21 アメリカ合衆国 癌抗原nyeso−1由来の新規mhcクラスii拘束t細胞エピトープ
AUPQ776100A0 (en) * 2000-05-26 2000-06-15 Australian National University, The Synthetic molecules and uses therefor
US6828329B2 (en) 2000-06-26 2004-12-07 Neurogen Corporation Aryl fused substituted 4-oxy-pyridines
US6506875B1 (en) * 2000-09-26 2003-01-14 Ludwig Institute For Cancer Research Isolated peptides which bind to HLA-C molecules and uses thereof
GB0030067D0 (en) 2000-12-11 2001-01-24 Univ Bristol Therapeutic agent
EP1229043A1 (en) 2001-01-30 2002-08-07 Cyto-Barr B.V. Peptides derived from Epstein Barr virus (EBV) proteins LMP1, LMP2 and BARF1 antibody reagents reactive therewith
WO2003008537A2 (en) 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
CA2478066C (en) 2001-12-04 2009-09-08 Ben-Gurion University Of The Negev Research And Development Authority Amphiphilic compounds and vesicles/liposomes for organ-specific drug targeting
WO2003104428A2 (en) 2002-01-21 2003-12-18 Vaccinex, Inc. Gene differentially expressed in breast and bladder cancer and encoded polypeptides
FR2836684B1 (fr) * 2002-03-04 2004-12-17 Inst Nat Sante Rech Med Peptides ras mutes et leur utilisation en immunotherapie
GB0214528D0 (en) 2002-06-24 2002-08-07 Univ Aberdeen Materials and methods for induction of immune tolerance
WO2004006952A2 (en) 2002-07-13 2004-01-22 Statens Serum Institut Therapeutic tuberculosis vaccines
WO2004014957A1 (en) 2002-08-12 2004-02-19 The Council Of The Queensland Institute Of Medical Research Novel immunogenic lipopeptides comprising t-helper and cytotoxic t lymphocyte (ctl) epitopes
KR101240547B1 (ko) 2002-08-12 2013-03-08 더 카운실 오브 더 퀸스랜드 인스티튜트 오브 메디칼 리서어치 T-헬퍼 및 b-세포 에피토프를 포함하는 신규한 면역원성리포펩타이드
WO2004041849A1 (en) 2002-11-07 2004-05-21 The Council Of The Queensland Institute Of Medical Research Epstein barr virus peptide epitopes, polyepitopes and delivery system therefor
US7491395B2 (en) 2002-11-20 2009-02-17 Bestewil Holding B.V. Compositions comprising antigen-complexes, method of making same as well as methods of using the antigen-complexes for vaccination
US20080139464A1 (en) * 2003-05-30 2008-06-12 Ludwig Institute Of Cancer Research Isolated Ny-Eso-1 Peptides Which Bind To Hla Class II Molecules And Uses Thereof
EP1664001A2 (en) 2003-07-29 2006-06-07 Rib-X Pharmaceuticals, Inc. Biaryl heterocyclic amines, amides, and sulfur-containing compounds and methods of making and using the same
CA2837748C (en) 2004-05-25 2016-03-08 Oregon Health And Science University Siv and hiv vaccination using rhcmv-and hcmv-based vaccine vectors
EP1666056A1 (en) 2004-12-06 2006-06-07 Bestewil Holding B.V. Cancer vaccine vesicles
JP5227592B2 (ja) 2005-02-07 2013-07-03 リポテック プロプライエタリー リミテッド アジュバント物質
FR2881746B1 (fr) 2005-02-07 2007-04-13 Centre Nat Rech Scient Epitopes t cd4+des antigenes de latence de type i et ii du virus epstein-barr aptes a etre reconnus par la majorite des individus de la population caucasienne et leurs applications
US20100129385A1 (en) 2005-02-08 2010-05-27 Jackson David C Immunogenic molecules
GB0507003D0 (en) * 2005-04-06 2005-05-11 Molmed Spa Therapeutic
CA2616906A1 (en) 2005-05-12 2006-11-23 Tapestry Pharmaceuticals, Inc. Molecular constructs suitable for targeted conjugates
WO2007044406A2 (en) * 2005-10-04 2007-04-19 Ludwig Institute For Cancer Research Methods for stimulating an immune response using bacterial antigen delivery system
JP2009511559A (ja) 2005-10-12 2009-03-19 バイオリポックス エービー 炎症の治療に有用なベンゾオキサゾール類
JP4824389B2 (ja) 2005-10-28 2011-11-30 株式会社医学生物学研究所 エプスタイン−バールウイルス感染細胞を特異的に攻撃する細胞傷害性t細胞エピトープペプチド及びその用途
KR20080098585A (ko) 2005-12-06 2008-11-11 새빈 테라퓨틱스 피티와이 엘티디 엡스타인-바르 바이러스 관련 질환의 치료
WO2007078879A2 (en) 2005-12-21 2007-07-12 Vaxinnate Corporation Lipopeptide compositions and methods of use thereof
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
US20090123488A1 (en) 2006-08-14 2009-05-14 Thymon, Llc Compositions and methods for the treatment and prophylaxis of Alzheimer's disease
MX2009007572A (es) 2007-01-15 2009-10-13 Glaxosmithkline Biolog Sa Proteinas de fusion que contienen los antigenos de rechazo de tumor ny-eso-1 y.
US8309096B2 (en) * 2007-01-15 2012-11-13 Glaxosmithkline Biologicals S.A. Fusion protein
CN106220721B (zh) 2007-03-26 2020-04-07 莱顿大学医学中心附属莱顿教学医院 Prame衍生的肽以及包括该肽的免疫原组合物
WO2008151197A2 (en) 2007-06-04 2008-12-11 The Regents Of The University Of California Tumor-derived endogenous toll-like receptor 4 ligands
US20100266623A1 (en) 2008-07-07 2010-10-21 The University Of Melbourne Synthetic, self adjuvanting vaccines
EP2320882A4 (en) 2008-07-07 2014-12-31 Univ Melbourne SYNTHETIC VACCINE COMPONENT
WO2010028246A2 (en) 2008-09-05 2010-03-11 Id Biomedical Corporation Of Quebec Novel compositions and adjuvants
EP2346830B1 (en) 2008-09-15 2015-05-13 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
EP2504315A1 (en) 2009-11-23 2012-10-03 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
EP2504330A1 (en) 2009-11-23 2012-10-03 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
WO2011109237A2 (en) 2010-03-02 2011-09-09 Emory University Uses of noscapine and derivatives in subjects diagnosed with fap
WO2011119628A2 (en) 2010-03-23 2011-09-29 The Regents Of The University Of California Compositions and methods for self-adjuvanting vaccines against microbes and tumors
US20130029358A1 (en) 2010-04-01 2013-01-31 Ludwig Institute For Cancer Research Ltd. Immunodominant mhc dr52b restricted ny-eso-1 epitopes, mhc class ii monomers and multimers, and uses thereof
WO2011156686A2 (en) 2010-06-11 2011-12-15 The Regents Of The University Of Colorado, A Body Corporate Method for synthesizing a cyclic multivalent peptide using a thiol-mediated reaction
WO2012020215A1 (en) 2010-08-09 2012-02-16 Centro Nacional De Investigaciones Oncológicas (Cnio) Amino- imidazolothiadiazoles for use as protein or lipid kinase inhibitors
WO2012025603A1 (en) 2010-08-25 2012-03-01 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) An epstein-barr-virus vaccine
US20140086888A1 (en) 2010-09-01 2014-03-27 Helen E. Heslop Ebv-specific cytotoxic t-lymphocytes for the treatment of locoregional nasopharyngeal carcinoma (npc)
US9340622B2 (en) 2010-09-14 2016-05-17 Council Of Scientific & Industrial Research Synthetic immunogen useful for generating long lasting immunity and protection against pathogens
BR112013006718B1 (pt) 2010-09-20 2021-12-07 Tron - Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberguniversität Mainz Gemeinnutzige Gmbh Receptor de células t com especificidade para ny-eso-1, composição farmacêutica compreendendo o mesmo e uso do mesmo
CN103189072B (zh) 2010-09-22 2018-02-09 因纳瓦克私人有限公司 免疫刺激方法
WO2012069188A1 (en) 2010-11-24 2012-05-31 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V Continuous flow processes for photoconjugation of high-molecular chemical entities
US9187534B2 (en) * 2011-03-11 2015-11-17 Universite De Geneve Multi-epitopic vaccine
US9402916B2 (en) 2011-03-17 2016-08-02 The University Of Birmingham Re-directed immunotherapy
SG194727A1 (en) 2011-05-13 2013-12-30 Univ Nanyang Tech Method for modification of organic molecules
US20120328660A1 (en) 2011-06-03 2012-12-27 Tsuji Takemasa Immunogenic compositions useful in provoking an integrated response to tumor antigens
CN102839186A (zh) * 2011-06-21 2012-12-26 上海生物制品研究所有限责任公司 表达ny-eso-1重组耻垢分枝杆菌的制备及应用
GB201114051D0 (en) 2011-08-15 2011-09-28 Domainex Ltd Compounds and their uses
US10406248B2 (en) * 2011-09-10 2019-09-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Molecular imaging of cancer cells in vivo
NL2007536C2 (en) 2011-10-05 2013-04-08 Academisch Ziekenhuis Leiden Lumc Adjuvant compound.
IN2014CN02581A (enExample) 2011-10-06 2015-08-07 Immunovaccine Technologies Inc
US9056141B2 (en) 2012-05-31 2015-06-16 Synchem, Inc. Thiol-ene click chemistry for drug conjugates
US9861702B2 (en) 2012-10-22 2018-01-09 Wisconsin Alumni Research Foundation Lipid-conjugated rhamnose for immune system recruitment and oncotherapy
WO2014088432A1 (en) * 2012-12-06 2014-06-12 Callaghan Innovation Research Limited Conjugate compounds
AU2014300503B2 (en) 2013-06-28 2018-11-22 Auckland Uniservices Limited Amino acid and peptide conjugates and conjugation process
RU2017126206A (ru) 2014-12-23 2019-01-25 Маргарет Анне БРИМБЛЕ Аминокислотные и пептидные конъюгаты и направления их использования
AU2017223267B2 (en) 2016-02-26 2021-07-22 Auckland Uniservices Limited Amino acid and peptide conjugates and conjugation process

Similar Documents

Publication Publication Date Title
JP2020023567A5 (enExample)
JP2010500399A5 (enExample)
JP2012500001A5 (enExample)
CA2187083C (fr) Fragment peptidique de la proteine g du virus respiratoire syncytial, agent immunogene, composition pharmaceutique le contenant et procede de preparation
FI3642340T3 (fi) Muunneltu l-asparaginaasi
JP2019533722A5 (enExample)
JP2005516885A5 (enExample)
JP2009292810A5 (enExample)
JP2018015005A5 (enExample)
JP2015517489A5 (enExample)
JP2017537611A5 (enExample)
JP2018506286A5 (enExample)
JP2014521684A5 (enExample)
JP2006506942A5 (enExample)
CN106232616A (zh) 两亲性合成抗菌肽、其药物组合物及其用途
JP2020536489A5 (enExample)
JP2020518287A5 (enExample)
JP2014529399A5 (enExample)
JP2020117504A5 (enExample)
CN109535232B (zh) 多肽、其制备方法及抑制艾滋病病毒的用途
JP2020509770A5 (enExample)
JP2018533908A5 (enExample)
JP2019534242A5 (enExample)
JP2009544304A5 (enExample)
JP2014515595A5 (enExample)